Global CD47 (IAP) 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR052502042

Publication Date:

May 5, 2025

Pages:

122

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global CD47 (IAP) market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

This report is a detailed and comprehensive analysis for global CD47 (IAP) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global CD47 (IAP) market size and forecasts, in consumption value ($ Million), 2020-2031
Global CD47 (IAP) market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global CD47 (IAP) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global CD47 (IAP) market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for CD47 (IAP)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global CD47 (IAP) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab, ImmuneOnco, Hengrui, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
CD47 (IAP) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
麻豆原创 segment by Application
Solid Tumor
Lymphoma
Others
麻豆原创 segment by players, this report covers
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe CD47 (IAP) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of CD47 (IAP), with revenue, gross margin, and global market share of CD47 (IAP) from 2020 to 2025.
Chapter 3, the CD47 (IAP) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and CD47 (IAP) market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of CD47 (IAP).
Chapter 13, to describe CD47 (IAP) research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of CD47 (IAP) by Type
1.3.1 Overview: Global CD47 (IAP) 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global CD47 (IAP) Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 CD47 Monoclonal Antibody
1.3.4 CD47 Double Antibody
1.3.5 CD47 Fusion Protein
1.4 Global CD47 (IAP) 麻豆原创 by Application
1.4.1 Overview: Global CD47 (IAP) 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Solid Tumor
1.4.3 Lymphoma
1.4.4 Others
1.5 Global CD47 (IAP) 麻豆原创 Size & Forecast
1.6 Global CD47 (IAP) 麻豆原创 Size and Forecast by Region
1.6.1 Global CD47 (IAP) 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global CD47 (IAP) 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America CD47 (IAP) 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe CD47 (IAP) 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific CD47 (IAP) 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America CD47 (IAP) 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa CD47 (IAP) 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Gilead
2.1.1 Gilead Details
2.1.2 Gilead Major Business
2.1.3 Gilead CD47 (IAP) Product and Solutions
2.1.4 Gilead CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Gilead Recent Developments and Future Plans
2.2 Innovent Biologics
2.2.1 Innovent Biologics Details
2.2.2 Innovent Biologics Major Business
2.2.3 Innovent Biologics CD47 (IAP) Product and Solutions
2.2.4 Innovent Biologics CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Innovent Biologics Recent Developments and Future Plans
2.3 Akeso, Inc
2.3.1 Akeso, Inc Details
2.3.2 Akeso, Inc Major Business
2.3.3 Akeso, Inc CD47 (IAP) Product and Solutions
2.3.4 Akeso, Inc CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Akeso, Inc Recent Developments and Future Plans
2.4 Arch Oncology
2.4.1 Arch Oncology Details
2.4.2 Arch Oncology Major Business
2.4.3 Arch Oncology CD47 (IAP) Product and Solutions
2.4.4 Arch Oncology CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Arch Oncology Recent Developments and Future Plans
2.5 ImmuneOncia Therapeutics
2.5.1 ImmuneOncia Therapeutics Details
2.5.2 ImmuneOncia Therapeutics Major Business
2.5.3 ImmuneOncia Therapeutics CD47 (IAP) Product and Solutions
2.5.4 ImmuneOncia Therapeutics CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 ImmuneOncia Therapeutics Recent Developments and Future Plans
2.6 I-MAB
2.6.1 I-MAB Details
2.6.2 I-MAB Major Business
2.6.3 I-MAB CD47 (IAP) Product and Solutions
2.6.4 I-MAB CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 I-MAB Recent Developments and Future Plans
2.7 Sorrento Therapeutics
2.7.1 Sorrento Therapeutics Details
2.7.2 Sorrento Therapeutics Major Business
2.7.3 Sorrento Therapeutics CD47 (IAP) Product and Solutions
2.7.4 Sorrento Therapeutics CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Sorrento Therapeutics Recent Developments and Future Plans
2.8 Zai Lab
2.8.1 Zai Lab Details
2.8.2 Zai Lab Major Business
2.8.3 Zai Lab CD47 (IAP) Product and Solutions
2.8.4 Zai Lab CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Zai Lab Recent Developments and Future Plans
2.9 ImmuneOnco
2.9.1 ImmuneOnco Details
2.9.2 ImmuneOnco Major Business
2.9.3 ImmuneOnco CD47 (IAP) Product and Solutions
2.9.4 ImmuneOnco CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 ImmuneOnco Recent Developments and Future Plans
2.10 Hengrui
2.10.1 Hengrui Details
2.10.2 Hengrui Major Business
2.10.3 Hengrui CD47 (IAP) Product and Solutions
2.10.4 Hengrui CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Hengrui Recent Developments and Future Plans
2.11 Beijing Mab-works
2.11.1 Beijing Mab-works Details
2.11.2 Beijing Mab-works Major Business
2.11.3 Beijing Mab-works CD47 (IAP) Product and Solutions
2.11.4 Beijing Mab-works CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Beijing Mab-works Recent Developments and Future Plans
2.12 Hanxbio
2.12.1 Hanxbio Details
2.12.2 Hanxbio Major Business
2.12.3 Hanxbio CD47 (IAP) Product and Solutions
2.12.4 Hanxbio CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Hanxbio Recent Developments and Future Plans
2.13 ALX Oncology
2.13.1 ALX Oncology Details
2.13.2 ALX Oncology Major Business
2.13.3 ALX Oncology CD47 (IAP) Product and Solutions
2.13.4 ALX Oncology CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 ALX Oncology Recent Developments and Future Plans
2.14 Surface Oncology
2.14.1 Surface Oncology Details
2.14.2 Surface Oncology Major Business
2.14.3 Surface Oncology CD47 (IAP) Product and Solutions
2.14.4 Surface Oncology CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Surface Oncology Recent Developments and Future Plans
2.15 TG Therapeutics
2.15.1 TG Therapeutics Details
2.15.2 TG Therapeutics Major Business
2.15.3 TG Therapeutics CD47 (IAP) Product and Solutions
2.15.4 TG Therapeutics CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 TG Therapeutics Recent Developments and Future Plans
2.16 EpicentRx
2.16.1 EpicentRx Details
2.16.2 EpicentRx Major Business
2.16.3 EpicentRx CD47 (IAP) Product and Solutions
2.16.4 EpicentRx CD47 (IAP) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 EpicentRx Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global CD47 (IAP) Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of CD47 (IAP) by Company Revenue
3.2.2 Top 3 CD47 (IAP) Players 麻豆原创 Share in 2024
3.2.3 Top 6 CD47 (IAP) Players 麻豆原创 Share in 2024
3.3 CD47 (IAP) 麻豆原创: Overall Company Footprint Analysis
3.3.1 CD47 (IAP) 麻豆原创: Region Footprint
3.3.2 CD47 (IAP) 麻豆原创: Company Product Type Footprint
3.3.3 CD47 (IAP) 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global CD47 (IAP) Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global CD47 (IAP) 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global CD47 (IAP) Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global CD47 (IAP) 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America CD47 (IAP) Consumption Value by Type (2020-2031)
6.2 North America CD47 (IAP) 麻豆原创 Size by Application (2020-2031)
6.3 North America CD47 (IAP) 麻豆原创 Size by Country
6.3.1 North America CD47 (IAP) Consumption Value by Country (2020-2031)
6.3.2 United States CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe CD47 (IAP) Consumption Value by Type (2020-2031)
7.2 Europe CD47 (IAP) Consumption Value by Application (2020-2031)
7.3 Europe CD47 (IAP) 麻豆原创 Size by Country
7.3.1 Europe CD47 (IAP) Consumption Value by Country (2020-2031)
7.3.2 Germany CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific CD47 (IAP) Consumption Value by Type (2020-2031)
8.2 Asia-Pacific CD47 (IAP) Consumption Value by Application (2020-2031)
8.3 Asia-Pacific CD47 (IAP) 麻豆原创 Size by Region
8.3.1 Asia-Pacific CD47 (IAP) Consumption Value by Region (2020-2031)
8.3.2 China CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America CD47 (IAP) Consumption Value by Type (2020-2031)
9.2 South America CD47 (IAP) Consumption Value by Application (2020-2031)
9.3 South America CD47 (IAP) 麻豆原创 Size by Country
9.3.1 South America CD47 (IAP) Consumption Value by Country (2020-2031)
9.3.2 Brazil CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa CD47 (IAP) Consumption Value by Type (2020-2031)
10.2 Middle East & Africa CD47 (IAP) Consumption Value by Application (2020-2031)
10.3 Middle East & Africa CD47 (IAP) 麻豆原创 Size by Country
10.3.1 Middle East & Africa CD47 (IAP) Consumption Value by Country (2020-2031)
10.3.2 Turkey CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE CD47 (IAP) 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 CD47 (IAP) 麻豆原创 Drivers
11.2 CD47 (IAP) 麻豆原创 Restraints
11.3 CD47 (IAP) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 CD47 (IAP) Industry Chain
12.2 CD47 (IAP) Upstream Analysis
12.3 CD47 (IAP) Midstream Analysis
12.4 CD47 (IAP) Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.